Table 1.
Demographic and clinical data in ALS patients and HCs.
| Items | HC (n = 25) | ALS (n = 18) | Statistical Value |
p Value |
|---|---|---|---|---|
| Age (years) | 53.40 ± 2.89 | 54.11 ± 12.09 | −0.24 | 0.78 b |
| Gender (male/female) | 17/8 | 9/9 | 1.42 | 0.23 a |
| MoCA | 27.88 ± 1.13 | 27.33 ± 0.84 | 1.73 | 0.09 b |
| Disease duration at baseline (months) | -- | 9.97 ± 8.45 | -- | -- |
| Site of onset (spinal/bulbar) | -- | 16/2 | -- | -- |
| ALSFRS-R at baseline (0–48) | -- | 41.89 ± 4.00 | -- | -- |
| ALSFRS-R progression rate [(48-ALSFRS-R score)/disease duration] | -- | 1.06 ± 0.97 | -- | -- |
| Diagnostic category (Definite/probable/probable lab-supported/possible) | -- | 14/3/1/0 | -- | -- |
Values are presented as the mean ± standard deviation. a p value was obtained by the χ2 test, b p value was obtained by two-sample t tests. Abbreviations: ALS, amyotrophic lateral sclerosis; HC, healthy control; MoCA, Montreal cognitive assessment; ALSFRS-R, the revised ALS functional rating scale.